NEW YORK--(BUSINESS WIRE)--The Klein Law Firm announces the commencement of an investigation of Meridian Bioscience, Inc. (NASDAQ: VIVO) concerning possible violations of federal securities laws.
On January 25, 2017, Meridian announced disappointing first-quarter 2017 fiscal year financial results, revised its previously-issued revenue guidance for the 2017 fiscal year downwards, and announced that the Board of Directors reduced the annual indicated dividend rate. Chief Executive Officer of Meridian, John A. Kraeutler, attributed the negative first quarter 2017 results to revenue declines in Meridian’s Americas diagnostic business—Meridian’s largest profit driver—across all major product categories, “due to customer buying patterns and general weakness overall.” On this news, shares of Meridian fell over 22% to close at $12.80 per share on January 25, 2017.
If you suffered a loss in Meridian and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kkclasslaw.com/VIVO-Info-Request-Form-180.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.